A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Allopurinol (Aloprim)

indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adu....

First FDA approval1986-10-24
Generic availableYes · 14 mfrs
Shortage statusDiscontinued
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$143.2M in CY2024 Part D spend14.6M claims · 4.5M beneficiaries · 329 plans surveyed

Lowest NADAC
$0.033/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.033
Across all dosage forms in distribution.
Highest NADAC
$0.033
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema12 entries indexed · 4 visible
What is Allopurinol used for?

indicated for: The management of adults with signs and symptoms of primary or secondary gout (acute attacks, tophi, joint destruction, uric acid lithiasis, and/or nephropathy) The management of adu....

Is there a generic for Allopurinol?

Yes. 29 ANDAs filed at FDA, 14 generic manufacturers currently shipping.

How much does my plan pay for Allopurinol?

Across 329 Part D plans, Allopurinol averages $0.033/unit (NADAC). Lowest available: $0.033/unit. Highest in distribution: $0.033/unit.

Is Allopurinol on the FDA shortage list?

Allopurinol has been discontinued by its manufacturer(s).

8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Xanthine Oxidase Inhibitor2 alternatives in D1
01
Febuxostat
Brand: ULORIC
$0.206Lowest NADAC
12Generic mfrs
$57.7MCY24 Part D spend
Compare →
02
Febuxostat Tablets
Brand: Febuxostat
$0.206Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.